Biosimilar User Fee Act III Regulatory Science Program Interim Public Meeting; Public Meeting; Request for Comments

1 organizations filed 1 public comment on Biosimilar User Fee Act III Regulatory Science Program Interim Public Meeting; Public Meeting; Request for Comments, at the Food and Drug Administration. The comment window closed 283d ago.

Commenters (1)

• Association for Accessible Medicinestrade assoc.

  1 filing · confidence 97%